Fertility — is it really a woman's problem?

If you're reading this because the diagnostic path so far has been entirely about you, you already suspect the answer. The data has been clear for two decades, and it isn't subtle: roughly half of fertility cases involve a male factor.

This post is the one we wished existed when our customers' partners — almost always women — were the ones who first reached out.

What the data actually says

Three numbers worth carrying with you:

~50%. A male factor is identified in roughly half of fertility cases — sometimes alone, often in combination with a female factor. The most-cited summary comes from ESHRE: in approximately 40–50% of investigated couples, male factors contribute. Some reviews put the figure higher when sub-clinical sperm DNA fragmentation is included.

12 months. That's the standard delay before male evaluation in most public-payer pathways. The widely-cited "12 months of trying before investigating" rule applies the same threshold to both partners, but in practice, female workup is offered earlier (cycle tracking, AMH, ultrasound) while the male side waits.

Two guidelines, one direction. The European Society of Human Reproduction and Embryology (ESHRE) and the American Urological Association (AUA) both recommend that male evaluation happen alongside female workup, not after it. The mismatch with how clinics actually run is a known issue in the literature.

Put together: half of the cases involve him, and yet the system tests him last. That's not biology. That's a leftover.

Why this gap persists

Three honest answers, stripped of euphemism.

The diagnostic infrastructure grew up around women's bodies. Reproductive medicine emerged from obstetrics and gynaecology. Andrology — the male equivalent — is a smaller, younger field with fewer specialists, fewer reimbursement codes, and a thinner footprint inside general practice. A GP can usually order an AMH; ordering a six-marker hormone panel is a different conversation.

Men are slower to ask. Surveys consistently show men are less likely to seek health advice, less likely to have a regular GP relationship, and more likely to assume that "feeling fine" rules out a problem. Most hormonal changes are silent. Most sperm changes are silent. Both can be measured in about a week.

Cost asymmetry has changed, but cultural framing hasn't. Until recently, male testing meant a clinic appointment, a referral, and a 4–6 week wait for a result that often included one or two markers. That made "skip it, see how it goes" reasonable. With at-home panels for ~€89 in 3–5 days, that calculus is different now. The framing — "fertility is a woman's question" — is a holdover from when the calculus was different.

What changes when you both test in parallel

Three concrete things.

Faster decisions. A specialist looking at both sides of a couple can plan an intervention strategy in one consultation; a specialist looking at only one side has to wait for the other. Studies on couples-based diagnostic protocols consistently find shorter time-to-decision when both partners arrive with data.

Less guesswork in the meantime. When you're trying and not succeeding, the months between tests are full of theories. Both panels reduce the theory space. They also remove the asymmetry — neither partner is the "default suspect" — which is mostly a relief.

Catch the upstream problems. A small but meaningful share of male infertility cases are caused by treatable upstream issues — hyperprolactinaemia, secondary hypogonadism, severe under-eating, opioid use. These respond well to specific treatment but are invisible without a hormone panel. Six markers cover all of them.

What to do this week

If you're the partner who reached this page first — and statistically, you are — here are three concrete moves, in increasing commitment:

1. Send him the 30-second quiz. Three questions, one tier-specific recommendation. He gets the answer to "should I test now?" without needing to make any decision in advance. Link: /quick-check.

2. Send him the full 2-minute quiz. Thirteen questions, scored against ESHRE and AUA guidance, returns a personalised risk band and a clear next step. Link: /quiz.

3. Order the panel. If you've already had the conversation, skip the funnels — €89, finger-prick kit ships within 24 hours, physician-reviewed report in 3–5 working days. Link: /checkout.

If you'd rather start from the data side, the /science page indexes the eleven primary sources we work from — the same ESHRE and AUA documents, the Levine 2017 sperm-decline meta-analysis, the Kong 2012 paternal-age mutation study, the Johnson 2015 age-effects review. We don't quote them; we link them.

A note on tone

We've spent the last six months talking to women who arrived at exactly this question. The most common worry isn't whether male testing is medically warranted — it obviously is. The worry is whether bringing it up will land badly with their partner.

The men we interviewed answered the opposite of what most women expected. The framing that worked was "the system is set up to test you last; that's a system problem; here's the panel that closes it." Almost no one took that as an accusation. Almost everyone took it as relief that someone had a structured way to ask.

If you'd rather have a script, the /for-her page has three of them — direct, soft, practical. Pick one.

The cheapest version of this whole post is one message: "Roughly half of fertility cases involve male factors. There's a six-marker home test for €89. Could you do it before our next appointment?"

That's it. That's the post.

Sources cited: ESHRE guideline group (workup of male and couple infertility), Levine et al. 2017 (sperm decline meta-analysis), Kong et al. 2012 (paternal-age mutations), Johnson et al. 2015 (age-effects review) — full entries on /science.